Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

$Results from the DELIVER and DAPA-HF Phase III trials demonstrate FARXIGA’s efficacy in heart failure regardless of ejection fraction$

News | Cardiovascular Clinical Studies

FARXIGA Met Primary Endpoint in DELIVER Phase III Trial

May 5, 2022 — High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a ...

May 05, 2022

News | Atrial Fibrillation

First Patients in the U.S. Enrolled in Biosense Webster Clinical Study To Evaluate VARIPULSE Catheter for Atrial Fibrillation

May 2, 2022 – Johnson & Johnson MedTech have announced that Biosense Webster, Inc., a worldwide leader in the science ...

May 02, 2022

Paragonix SherpaPak Cardiac Transport System

News | Cardiovascular Surgery

Paragonix Technologies SherpaPak Improves 1-Year Survival in Heart Transplant Patients in Real-World Study

April 29, 2022 – Paragonix Technologies, Inc., a leading organ preservation provider, announces today groundbreaking ...

April 29, 2022

Aurora St. Luke’s Medical Center in Milwaukee is the first site in the country to join a clinical trial studying machine-learning software designed to help novice users perform an echocardiography exam.

News | Cardiovascular Ultrasound

Study Evaluates AI Software that Aids Novice Users Performing Echocardiogram

April 29, 2022 – Aurora St. Luke’s Medical Center in Milwaukee is the first site in the country to join a clinical trial ...

April 29, 2022

Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo

News | Pharmaceuticals

FDA Approves Bristol Myers' Camzyos (mavacamten) Oral Heart Disease Drug

April 29, 2022 — Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Camzyos ...

April 29, 2022

CathVision, a medical technology company developing innovative electrophysiology solutions designed to guide and enhance cardiac ablation therapy through the acquisition of low-noise, high-fidelity electrograms, announced the completion of patient enrollment in the CathVision ECGenius System clinical evaluation study at the University of Vermont Medical Center.

News | EP Lab

CathVision Announces Completion of Patient Enrollment at First U.S. Clinical Trial Evaluating High-Fidelity, Low-Noise EP Recording Technology

April 27, 2022 – CathVision, a medical technology company developing innovative electrophysiology solutions designed to ...

April 27, 2022

MIVI Neuroscience, Inc., innovator of the next generation of neurointerventional medical devices, today announced the first patient enrollments in a multicenter clinical study to assess the safety and performance of the Q Aspiration Catheter used in a combined aspiration with stent-retriever technique for thrombus removal in patients who have suffered an acute ischemic stroke.

News | Catheters

MIVI Neuroscience Launches Largest Study Yet of its Aspiration Catheter for Thrombus Removal

April 21, 2022 – MIVI Neuroscience, Inc., innovator of the next generation of neurointerventional medical devices, today ...

April 21, 2022

Researchers from the RIKEN Center for Advanced Intelligence Project (AIP) and colleagues have tested AI-enhanced diagnosis of fetal congenital heart disease in a clinical setting.

News | Cardiovascular Ultrasound

Doctors Diagnosing Fetal Heart Disease Benefit from Explanatory AI

April 20, 2022 – Researchers from the RIKEN Center for Advanced Intelligence Project (AIP) and colleagues have tested ...

April 20, 2022

A new study finds that a history of infertility is associated with increased risk of heart failure.

News | Womens Cardiovascular Health

Study Finds Infertility History Linked with Increased Risk of Heart Failure

April 20, 2022 – A new study finds that a history of infertility is associated with increased risk of heart failure ...

April 20, 2022

New breakthrough research by a University of South Florida lab team describing how certain fats can harm or repair the heart after injury has been accepted by a journal of the American Physiological Society.

News | Heart Failure

Quality of Fat Input Determines Output of Kidney and Cardiac Health and Repair, says USF Health Study

April 19, 2022 – New breakthrough research by a University of South Florida lab team describing how certain fats can ...

April 19, 2022

Eleven teams of scientific researchers have been selected as recipients of American Heart Association research grants to study the long-term influence of COVID-19 on cardiovascular health.

News | Coronavirus (COVID-19)

More than $10M in Research Grants Awarded to Study Long COVID Impact on CVD Health

April 18, 2022 — Eleven teams of scientific researchers have been selected as recipients of American Heart Association r ...

April 18, 2022

News | Coronavirus (COVID-19)

More Than $10M in Research Grants Awarded to Study Long COVID Impact on CVD Health

April 15, 2022 — Eleven teams of scientific researchers have been selected as recipients of American Heart Association r ...

April 15, 2022

News | Atrial Fibrillation

Zio by iRhythm Shown to Prevent Hospital Admissions, Aid in Early Detection of AF

April 12, 2022 – iRhythm Technologies, Inc., a leading digital healthcare solutions company focused on the advancement ...

April 12, 2022

Physicians prescribed significantly more guideline-directed medications for heart failure if they received a customized digital alert via an electronic health record (EHR) system when inputting medical orders shortly after seeing a patient, according to a study presented at the American College of Cardiology’s 71st Annual Scientific Session.

News | Heart Failure

Electronic Alert Improves Guideline Adherence for Heart Failure Treatment

April 8, 2022 – Physicians prescribed significantly more guideline-directed medications for heart failure if they ...

April 08, 2022

Patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) medications for heart failure had significantly lower blood potassium levels when taking patiromer—a drug that helps to prevent the body from absorbing too much potassium—compared with a placebo, in a study presented at the American College of Cardiology’s 71st Annual Scientific Session.

News | Heart Failure

Patiromer Helps Patients Stay on Optimal Heart Failure Therapy

April 8, 2022 – Patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) medications for heart failure had ...

April 08, 2022